171 related articles for article (PubMed ID: 16574044)
1. Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus: meta-analysis of randomised controlled trials.
Allemann S; Diem P; Egger M; Christ ER; Stettler C
Curr Med Res Opin; 2006 Mar; 22(3):617-23. PubMed ID: 16574044
[TBL] [Abstract][Full Text] [Related]
2. Is it time to stop treating dyslipidaemia with fibrates?
Benatar JR; Stewart RA
N Z Med J; 2007 Sep; 120(1261):U2706. PubMed ID: 17853928
[TBL] [Abstract][Full Text] [Related]
3. Tissue ACE inhibitors for secondary prevention of cardiovascular disease in patients with preserved left ventricular function: a pooled meta-analysis of randomized placebo-controlled trials.
Saha SA; Molnar J; Arora RR
J Cardiovasc Pharmacol Ther; 2007 Sep; 12(3):192-204. PubMed ID: 17875946
[TBL] [Abstract][Full Text] [Related]
4. Fenofibrate therapy and cardiovascular protection in diabetes: recommendations after FIELD.
Vergès B
Curr Opin Lipidol; 2006 Dec; 17(6):653-8. PubMed ID: 17095910
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN).
Knopp RH; d'Emden M; Smilde JG; Pocock SJ
Diabetes Care; 2006 Jul; 29(7):1478-85. PubMed ID: 16801565
[TBL] [Abstract][Full Text] [Related]
6. Fibrates in the treatment of cardiovascular risk and atherogenic dyslipidaemia.
Wierzbicki AS
Curr Opin Cardiol; 2009 Jul; 24(4):372-9. PubMed ID: 19424060
[TBL] [Abstract][Full Text] [Related]
7. Effects of intensive glucose control on incidence of cardiovascular events in patients with type 2 diabetes: a meta-analysis.
Zhang CY; Sun AJ; Zhang SN; Wu CN; Fu MQ; Xia G; Wang KQ; Zou YZ; Ge JB
Ann Med; 2010 May; 42(4):305-15. PubMed ID: 20429797
[TBL] [Abstract][Full Text] [Related]
8. Role of aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: a meta-analysis.
Younis N; Williams S; Ammori B; Soran H
Expert Opin Pharmacother; 2010 Jun; 11(9):1459-66. PubMed ID: 20429671
[TBL] [Abstract][Full Text] [Related]
9. Role for fibrate therapy in diabetes: evidence before FIELD.
Vergès B
Curr Opin Lipidol; 2005 Dec; 16(6):648-51. PubMed ID: 16276243
[TBL] [Abstract][Full Text] [Related]
10. FIELDS of dreams, fields of tears: a perspective on the fibrate trials.
Wierzbicki AS
Int J Clin Pract; 2006 Apr; 60(4):442-9. PubMed ID: 16620358
[TBL] [Abstract][Full Text] [Related]
11. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people.
Schramm TK; Gislason GH; Køber L; Rasmussen S; Rasmussen JN; Abildstrøm SZ; Hansen ML; Folke F; Buch P; Madsen M; Vaag A; Torp-Pedersen C
Circulation; 2008 Apr; 117(15):1945-54. PubMed ID: 18378618
[TBL] [Abstract][Full Text] [Related]
12. Effects of statins on stroke prevention in patients with and without coronary heart disease: a meta-analysis of randomized controlled trials.
Briel M; Studer M; Glass TR; Bucher HC
Am J Med; 2004 Oct; 117(8):596-606. PubMed ID: 15465509
[TBL] [Abstract][Full Text] [Related]
13. Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis.
Zhang C; Sun A; Zhang P; Wu C; Zhang S; Fu M; Wang K; Zou Y; Ge J
Diabetes Res Clin Pract; 2010 Feb; 87(2):211-8. PubMed ID: 19853947
[TBL] [Abstract][Full Text] [Related]
14. Xuezhikang, an extract of cholestin, reduces cardiovascular events in type 2 diabetes patients with coronary heart disease: subgroup analysis of patients with type 2 diabetes from China coronary secondary prevention study (CCSPS).
Zhao SP; Lu ZL; Du BM; Chen Z; Wu YF; Yu XH; Zhao YC; Liu L; Ye HJ; Wu ZH;
J Cardiovasc Pharmacol; 2007 Feb; 49(2):81-4. PubMed ID: 17312447
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and tolerability of administration of granulocyte colony-stimulating factor on left ventricular function in patients with myocardial infarction: a meta-analysis of randomized controlled trials.
Kang S; Yang Y; Li CJ; Gao R
Clin Ther; 2007 Nov; 29(11):2406-18. PubMed ID: 18158081
[TBL] [Abstract][Full Text] [Related]
16. Is fenofibrate a cost-saving treatment for middle-aged individuals with type II diabetes? An economic analysis of the FIELD Study.
Carrington M; Stewart S
Int J Cardiol; 2008 Jun; 127(1):51-6. PubMed ID: 17586072
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of recent lipid trials on reducing risk in patients with type 2 diabetes mellitus.
Jones PH
Am J Cardiol; 2007 Feb; 99(4A):133B-140B. PubMed ID: 17307065
[TBL] [Abstract][Full Text] [Related]
18. Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials.
Mannucci E; Monami M; Lamanna C; Gori F; Marchionni N
Nutr Metab Cardiovasc Dis; 2009 Nov; 19(9):604-12. PubMed ID: 19427768
[TBL] [Abstract][Full Text] [Related]
19. Lipids in type 2 diabetes.
Laakso M
Semin Vasc Med; 2002 Feb; 2(1):59-66. PubMed ID: 16222596
[TBL] [Abstract][Full Text] [Related]
20. [Favorable effects of decreasing lipids in patients with diabetes mellitus].
Gouni-Berthold I; Krone W
Dtsch Med Wochenschr; 2006 Dec; 131 Suppl 8():S252-4. PubMed ID: 17139581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
